查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179610

自閉症譜系障礙市場：按疾病（自閉症、阿斯伯格綜合症、廣泛性發育障礙等）、服務、地區劃分：2021-2031 年全球機會分析和行業預測

Autism Spectrum Disorders Market By Disease (Autistic Disorder, Asperger Syndrome, Pervasive development disorder, Other), By Service, By Location : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 300 Pages | 商品交期: 2-3個工作天內

價格

全球自閉症譜系障礙治療市場預計到 2021 年將達到 272.727 億美元，到 2031 年將達到 431.6616 億美元，2022 年至 2031 年的複合年增長率為 4.6%。

一組被稱為自閉症譜系障礙 (ASD) 的晚期神經系統疾病的特徵是行為模式範圍廣泛以及社交互動和溝通困難。強迫行為、錯誤的社交互動、學習障礙、焦慮、聽覺過敏、重複動作和許多其他特徵是 ASD 的主要體徵和症狀。

自閉症譜系障礙患病率的增加和對早期診斷的需求不斷增加正在推動市場的增長。例如，2021 年 11 月，本古裡安大學研究人員的一項研究發現，與晚年診斷相比，在 2.5 歲時診斷出自閉症譜系障礙可顯著改善社交症狀。事實證明。因此，提高對自閉症譜系障礙的認識以及對自閉症譜系障礙早期診斷的需求增加正在推動市場增長。

此外，自閉症譜系障礙患病率的增加和對自閉症譜系障礙服務意識的提高是推動自閉症譜系障礙治療市場增長的關鍵因素。例如，2022 年 3 月，世界衛生組織 (WHO) 的一份報告估計，全世界大約每 100 名兒童中就有 1 名患有自閉症譜系障礙。

此外，人們對自閉症譜系障礙的認識不斷提高，政府和非政府組織為自閉症譜系障礙提供診斷和服務的貢獻也在不斷增加，這些都推動了市場的增長。例如，ASERT（自閉症服務、教育、資源和培訓）是一個由醫療中心、大學和計劃組成的組織，旨在提高患有自閉症譜系障礙 (ASD) 的年輕人的獨立性和減少孤立感。，宣布推出自閉症意識, 社區教育和支持 (AACES)。

此外，市場受到先進自閉症譜系障礙治療的研發活動增加、疾病診斷的進步、美國食品和藥物管理局 (USFDA) 批准的增加以及主要參與者在市場上推出新產品的推動。正在支持的增長例如，2021 年 10 月，致力於改善神經障礙和疾病患者生活的臨床階段生物製藥公司 Axial Therapeutics 宣布了主要候選藥物 AB-2004（與自閉症譜系障礙相關）獲得美國食品和藥物管理局的批准藥物管理局 (FDA) 的研究性新藥 (IND) 申請，用於針對超敏反應服務的腸道靶向分子治療。此外，自閉症譜系障礙治療的進步，如在線培訓平台和自閉症譜系障礙的移動疾病，將進一步促進市場增長。然而，自閉症譜系障礙治療的高成本和對該疾病缺乏認識可能會阻礙市場增長。

自閉症譜系障礙治療市場根據服務、疾病、地點和地區進行細分。按服務方式分為行為治療、早期干預、藥物治療等。

按疾病分類，可分為自閉症、阿斯伯格綜合症和廣泛性發育障礙（PDD）。

目錄

第 1 章 簡介

第二章執行摘要

第三章市場概況

  • 市場定義和範圍
  • 主要發現
    • 主要投資機會
  • 波特五力分析
  • 大公司定位
  • 市場動態
    • 促進者
    • 抑製劑
    • 機會
  • COVID-19 影響分析

4 自閉症譜系障礙市場，按疾病分類

  • 概述
    • 市場規模和預測
  • 自閉症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 阿斯伯格綜合症
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 廣泛性發育障礙 (PDD)
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

5. 自閉症譜系障礙市場，按服務分類

  • 概述
    • 市場規模/預測
  • 行為方法
    • 主要市場趨勢、增長因素和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 按行為方法劃分的自閉症譜系障礙市場：性別
      • 男裝市場規模及預測：按地區
      • 女性市場規模趨勢和預測：按地區
  • 早期干涉
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 早期干預自閉症譜系障礙市場：性別
      • 男裝市場規模及預測：按地區
      • 女性市場規模趨勢和預測：按地區
  • 藥物治療
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 藥物療法自閉症譜系障礙市場：性別
      • 男裝市場規模及預測：按地區
      • 女性市場規模趨勢和預測：按地區
  • 其他服務
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
    • 自閉症譜系障礙市場的其他服務：性別
      • 男裝市場規模及預測：按地區
      • 女性市場規模趨勢和預測：按地區

6. 按地區劃分的自閉症譜系障礙市場

  • 概述
    • 市場規模/預測
  • 醫院
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 教育輔導中心
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類
  • 其他
    • 主要市場趨勢、增長動力和機遇
    • 市場規模/預測：按地區
    • 市場分析：按國家分類

7. 自閉症譜系障礙市場，按地區

  • 概述
    • 市場規模/預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按疾病分類
    • 北美市場規模和預測：按服務分類
      • 按行為方法劃分的北美自閉症譜系障礙市場：性別歧視
      • 北美早期干預自閉症譜系障礙市場，按性別
      • 按藥物、性別分列的北美自閉症譜系障礙市場
      • 北美其他服務自閉症譜系障礙市場，按性別
    • 北美市場規模和預測：按地點
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模/預測：按疾病分類
    • 歐洲市場規模和預測：按服務分類
      • 按行為方法劃分的歐洲自閉症譜系障礙市場：按性別
      • 歐洲早期干預自閉症譜系障礙市場：性別歧視
      • 歐洲藥物治療自閉症譜系障礙市場，按性別分類
      • 歐洲其他服務自閉症譜系障礙市場，按性別分類
    • 歐洲市場規模和預測：按地點
    • 歐洲市場規模和預測：按國家分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 歐洲其他地區
  • 亞太地區
    • 主要趨勢和機遇
    • 亞太地區按疾病劃分的市場規模和預測
    • 亞太市場規模及預測：按服務分類
      • 亞太地區自閉症譜系障礙市場，按行為方式，按性別
      • 亞太地區早期干預自閉症譜系障礙市場，按性別分類
      • 亞太藥物治療自閉症譜系障礙市場，按性別分類
      • 亞太自閉症譜系障礙市場：其他服務，按性別分類
    • 亞太市場規模和預測：按地點分類
    • 亞太市場規模和預測：按國家分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 亞太其他地區
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機遇
    • 拉丁美洲、中東和非洲的市場規模和預測：按疾病分類
    • 拉丁美洲/中東/非洲市場規模/預測：按服務分類
      • 拉丁美洲、中東和非洲自閉症譜系障礙市場，按行為方法，按性別
      • 拉丁美洲/中東/非洲早期干預自閉症譜系障礙市場，按性別分類
      • 拉丁美洲/中東/非洲自閉症譜系障礙市場（按藥物療法，按性別）
      • 拉丁美洲/中東/非洲其他服務自閉症譜系障礙市場，按性別
    • 拉丁美洲/中東/非洲市場規模/預測：按地點
    • 拉丁美洲/中東/非洲市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • 南非共和國
      • 拉丁美洲其他地區/中東/非洲

第八章 公司情況

  • 介紹
  • 關鍵成功策略
  • 10大公司產品圖
  • 比賽儀表板
  • 競爭熱圖
  • 重大發展

第九章公司簡介

  • Abbvie Inc
  • Axial therapeutics
  • Bristol Myers Squibb Co.
  • Cognoa Inc
  • Curemark LLC
  • dfusion inc.
  • EarliTec Diagnostics Inc
  • Jazz Pharmaceuticals
  • Johnson & Johnson
  • Novartis AG
Product Code: A13338

The global autism spectrum disorder treatment market was valued at $27,272.7 million in 2021, and is projected to reach $43,166.16 million by 2031, registering a CAGR of 4.6% from 2022 to 2031.

A class of sophisticated neurological illnesses known as autism spectrum disorder (ASD) is characterized by a wide range of behavioral patterns and difficulties with social interaction and communication. Compulsive behavior, incorrect social interaction, a learning handicap, anxiety, sensitivity to hearing, repetitive motions, and many other characteristics are among the key indications and symptoms of ASD.

The increase in prevalence of autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorders boost the growth of market. For instance, in November 2021, as per the study of Ben-Gurion University researchers and colleagues, it was found that, autism spectrum disorder diagnosis by 2.5 years of age leads to dramatic improvements in social symptoms as compared to those diagnosed later in life. Thus, rise in awareness about autism spectrum disorder and rise in demand for early diagnosis of autism spectrum disorder drive the growth of market.

Moreover, the increase in prevalence of autism spectrum disorder and rise in awareness regarding service of autism spectrum disorder are the key factors that drive the growth of autism spectrum disorder treatment market. For instance, in March 2022, as per the report of World Health Organization (WHO), it was estimated that worldwide about one in 100 children has autism spectrum disorder.

Furthermore, the increase in awareness about autism spectrum disorder and rise in contribution of government & non-government organizations to provide autism spectrum disorder diagnosis & service propel the growth of market. For instance, ASERT (Autism Services, Education, Resources and Training) is an organization of medical centers, and universities, announced the launch of Autism Awareness, Community Education and Support (AACES), a program designed to increase independence and decrease isolation among young people with autism spectrum disorder (ASD).

Moreover, the increase in R&D activities for development of advanced autism spectrum disorder treatment, advancements in diagnosis of disease, rise in U.S. food and drug administration (USFDA) approvals, and novel product launch in market by key players boost the market growth. For instance, in October 2021, Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological disorders and diseases, received clearance from the U.S. Food and Drug Administration (FDA) of its investigational new drug (IND) application for lead candidate, AB-2004, a gut-targeted, molecular therapeutic for the service of irritability associated with autism spectrum disorder. Furthermore, advancements in autism spectrum disorder treatments such as online training platforms and mobile diseases for autism spectrum further contribute in market growth. However, the high cost of autism spectrum disorder treatment and lack of awareness about disease may hinder the growth of market.

The Autism spectrum disorder treatment market is segmented on the basis of service, disease, location and region. By service , the market is classified into behavioral approaches, early intervention, medication, and others.

Depending on disease, the market is classified into autistic disorder, asperger's syndrome, and pervasive development disorder (PDD).

By location, market is categorized into hospital, education counsellor center, and others. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

  • The major companies profiled in the report include: Abbvie Inc, Axial therapeutics, The Bristol Myers Squibb Company, Cognoa Inc, Curemark LLC, Dfusion Inc, EarliTec Diagnostics Inc, Jaguar Gene Therapy, Jazz Pharmaceuticals, Johnson & Johnson, Neurim Pharmaceuticals Ltd., Novartis AG, PaxMedica Inc, Pfizer Inc, Stalicla SA, Teva Pharmaceutical Industries Ltd. and Yamo Pharmaceuticals LLC.
  • Key Benefits For Stakeholders
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the autism spectrum disorders market analysis from 2021 to 2031 to identify the prevailing autism spectrum disorders market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the autism spectrum disorders market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global autism spectrum disorders market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Disease

  • Autistic Disorder
  • Asperger Syndrome
  • Pervasive development disorder (PDD)
  • Other

By Service

  • Behavioural Approaches
    • Gender
    • Male
    • Female
  • Early Intervention
    • Gender
    • Male
    • Female
  • Medication
    • Gender
    • Male
    • Female
  • Other Services
    • Gender
    • Male
    • Female

By Location

  • Hospitals
  • Education Counsellor Center
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbvie Inc
    • Axial therapeutics
    • Bristol Myers Squibb Co.
    • Cognoa Inc
    • Curemark LLC
    • dfusion inc.
    • EarliTec Diagnostics Inc
    • Jazz Pharmaceuticals
    • Johnson & Johnson
    • Novartis AG

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Autistic Disorder
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Asperger Syndrome
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Pervasive development disorder (PDD)
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Other
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Behavioural Approaches
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
    • 5.2.4 Behavioural Approaches Autism Spectrum Disorders Market by Gender
      • 5.2.4.1 Male Market size and forecast, by region
      • 5.2.4.2 Female Market size and forecast, by region
  • 5.3 Early Intervention
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
    • 5.3.4 Early Intervention Autism Spectrum Disorders Market by Gender
      • 5.3.4.1 Male Market size and forecast, by region
      • 5.3.4.2 Female Market size and forecast, by region
  • 5.4 Medication
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country
    • 5.4.4 Medication Autism Spectrum Disorders Market by Gender
      • 5.4.4.1 Male Market size and forecast, by region
      • 5.4.4.2 Female Market size and forecast, by region
  • 5.5 Other Services
    • 5.5.1 Key market trends, growth factors and opportunities
    • 5.5.2 Market size and forecast, by region
    • 5.5.3 Market analysis by country
    • 5.5.4 Other Services Autism Spectrum Disorders Market by Gender
      • 5.5.4.1 Male Market size and forecast, by region
      • 5.5.4.2 Female Market size and forecast, by region

CHAPTER 6: AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Education Counsellor Center
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Others
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: AUTISM SPECTRUM DISORDERS MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Disease
    • 7.2.3 North America Market size and forecast, by Service
      • 7.2.3.1 North America Behavioural Approaches Autism Spectrum Disorders Market by Gender
      • 7.2.3.2 North America Early Intervention Autism Spectrum Disorders Market by Gender
      • 7.2.3.3 North America Medication Autism Spectrum Disorders Market by Gender
      • 7.2.3.4 North America Other Services Autism Spectrum Disorders Market by Gender
    • 7.2.4 North America Market size and forecast, by Location
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Disease
      • 7.2.5.1.2 Market size and forecast, by Service
      • 7.2.5.1.3 Market size and forecast, by Location
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Disease
      • 7.2.5.2.2 Market size and forecast, by Service
      • 7.2.5.2.3 Market size and forecast, by Location
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Disease
      • 7.2.5.3.2 Market size and forecast, by Service
      • 7.2.5.3.3 Market size and forecast, by Location
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Disease
    • 7.3.3 Europe Market size and forecast, by Service
      • 7.3.3.1 Europe Behavioural Approaches Autism Spectrum Disorders Market by Gender
      • 7.3.3.2 Europe Early Intervention Autism Spectrum Disorders Market by Gender
      • 7.3.3.3 Europe Medication Autism Spectrum Disorders Market by Gender
      • 7.3.3.4 Europe Other Services Autism Spectrum Disorders Market by Gender
    • 7.3.4 Europe Market size and forecast, by Location
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Disease
      • 7.3.5.1.2 Market size and forecast, by Service
      • 7.3.5.1.3 Market size and forecast, by Location
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Disease
      • 7.3.5.2.2 Market size and forecast, by Service
      • 7.3.5.2.3 Market size and forecast, by Location
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Disease
      • 7.3.5.3.2 Market size and forecast, by Service
      • 7.3.5.3.3 Market size and forecast, by Location
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Disease
      • 7.3.5.4.2 Market size and forecast, by Service
      • 7.3.5.4.3 Market size and forecast, by Location
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Disease
      • 7.3.5.5.2 Market size and forecast, by Service
      • 7.3.5.5.3 Market size and forecast, by Location
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Disease
      • 7.3.5.6.2 Market size and forecast, by Service
      • 7.3.5.6.3 Market size and forecast, by Location
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Disease
    • 7.4.3 Asia-Pacific Market size and forecast, by Service
      • 7.4.3.1 Asia-Pacific Behavioural Approaches Autism Spectrum Disorders Market by Gender
      • 7.4.3.2 Asia-Pacific Early Intervention Autism Spectrum Disorders Market by Gender
      • 7.4.3.3 Asia-Pacific Medication Autism Spectrum Disorders Market by Gender
      • 7.4.3.4 Asia-Pacific Other Services Autism Spectrum Disorders Market by Gender
    • 7.4.4 Asia-Pacific Market size and forecast, by Location
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Disease
      • 7.4.5.1.2 Market size and forecast, by Service
      • 7.4.5.1.3 Market size and forecast, by Location
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Disease
      • 7.4.5.2.2 Market size and forecast, by Service
      • 7.4.5.2.3 Market size and forecast, by Location
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Disease
      • 7.4.5.3.2 Market size and forecast, by Service
      • 7.4.5.3.3 Market size and forecast, by Location
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Disease
      • 7.4.5.4.2 Market size and forecast, by Service
      • 7.4.5.4.3 Market size and forecast, by Location
      • 7.4.5.5 Rest of Asia-Pacific
      • 7.4.5.5.1 Market size and forecast, by Disease
      • 7.4.5.5.2 Market size and forecast, by Service
      • 7.4.5.5.3 Market size and forecast, by Location
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Disease
    • 7.5.3 LAMEA Market size and forecast, by Service
      • 7.5.3.1 LAMEA Behavioural Approaches Autism Spectrum Disorders Market by Gender
      • 7.5.3.2 LAMEA Early Intervention Autism Spectrum Disorders Market by Gender
      • 7.5.3.3 LAMEA Medication Autism Spectrum Disorders Market by Gender
      • 7.5.3.4 LAMEA Other Services Autism Spectrum Disorders Market by Gender
    • 7.5.4 LAMEA Market size and forecast, by Location
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Disease
      • 7.5.5.1.2 Market size and forecast, by Service
      • 7.5.5.1.3 Market size and forecast, by Location
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Disease
      • 7.5.5.2.2 Market size and forecast, by Service
      • 7.5.5.2.3 Market size and forecast, by Location
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Disease
      • 7.5.5.3.2 Market size and forecast, by Service
      • 7.5.5.3.3 Market size and forecast, by Location
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Disease
      • 7.5.5.4.2 Market size and forecast, by Service
      • 7.5.5.4.3 Market size and forecast, by Location

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Abbvie Inc
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Axial therapeutics
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bristol Myers Squibb Co.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Cognoa Inc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Curemark LLC
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 dfusion inc.
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 EarliTec Diagnostics Inc
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Jazz Pharmaceuticals
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Johnson & Johnson
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Novartis AG
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 2. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR AUTISTIC DISORDER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. AUTISM SPECTRUM DISORDERS MARKET FOR AUTISTIC DISORDER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR ASPERGER SYNDROME, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. AUTISM SPECTRUM DISORDERS MARKET FOR ASPERGER SYNDROME, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR PERVASIVE DEVELOPMENT DISORDER (PDD), BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. AUTISM SPECTRUM DISORDERS MARKET FOR PERVASIVE DEVELOPMENT DISORDER (PDD), BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. AUTISM SPECTRUM DISORDERS MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 11. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR BEHAVIOURAL APPROACHES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. AUTISM SPECTRUM DISORDERS MARKET FOR BEHAVIOURAL APPROACHES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. GLOBAL BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 14. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR EARLY INTERVENTION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 17. AUTISM SPECTRUM DISORDERS MARKET FOR EARLY INTERVENTION, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 18. GLOBAL EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 19. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 21. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR MEDICATION, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. AUTISM SPECTRUM DISORDERS MARKET FOR MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. GLOBAL MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 24. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 25. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 26. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHER SERVICES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 27. AUTISM SPECTRUM DISORDERS MARKET FOR OTHER SERVICES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. GLOBAL OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 29. AUTISM SPECTRUM DISORDERS MARKET, FOR MALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 30. AUTISM SPECTRUM DISORDERS MARKET, FOR FEMALE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 31. GLOBAL AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 32. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 33. AUTISM SPECTRUM DISORDERS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 34. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR EDUCATION COUNSELLOR CENTER, BY REGION, 2021-2031 ($MILLION)
  • TABLE 35. AUTISM SPECTRUM DISORDERS MARKET FOR EDUCATION COUNSELLOR CENTER, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 36. AUTISM SPECTRUM DISORDERS MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 37. AUTISM SPECTRUM DISORDERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 38. AUTISM SPECTRUM DISORDERS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 39. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 40. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 41. NORTH AMERICA BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 42. NORTH AMERICA EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 43. NORTH AMERICA MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 44. NORTH AMERICA OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 45. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 46. NORTH AMERICA AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 47. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 48. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 49. U.S. AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 50. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 51. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 52. CANADA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 53. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 54. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 55. MEXICO AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 56. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 57. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 58. EUROPE BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 59. EUROPE EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 60. EUROPE MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 61. EUROPE OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 62. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 63. EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 64. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 65. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 66. GERMANY AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 67. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 68. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 69. FRANCE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 70. UK AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 71. UK AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 72. UK AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 73. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 74. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 75. ITALY AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 76. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 77. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 78. SPAIN AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 79. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 80. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 81. REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 82. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 83. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 84. ASIA-PACIFIC BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 85. ASIA-PACIFIC EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 86. ASIA-PACIFIC MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 87. ASIA-PACIFIC OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 88. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 89. ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 90. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 91. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 92. JAPAN AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 93. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 94. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 95. CHINA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 96. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 97. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 98. AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 99. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 100. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 101. INDIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 102. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 103. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 104. REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 105. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 106. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 107. LAMEA BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 108. LAMEA EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 109. LAMEA MEDICATION AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 110. LAMEA OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET, BY GENDER, 2021-2031 ($MILLION)
  • TABLE 111. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 112. LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 113. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 114. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 115. BRAZIL AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 116. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 117. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 118. SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 119. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 120. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 121. SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 122. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY DISEASE, 2021-2031 ($MILLION)
  • TABLE 123. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY SERVICE, 2021-2031 ($MILLION)
  • TABLE 124. REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET, BY LOCATION, 2021-2031 ($MILLION)
  • TABLE 125.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 126.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 127.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 128.ABBVIE INC: NET SALES,
  • TABLE 129.ABBVIE INC: KEY STRATERGIES
  • TABLE 130.AXIAL THERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 131.AXIAL THERAPEUTICS: OPERATING SEGMENTS
  • TABLE 132.AXIAL THERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 133.AXIAL THERAPEUTICS: NET SALES,
  • TABLE 134.AXIAL THERAPEUTICS: KEY STRATERGIES
  • TABLE 135.BRISTOL MYERS SQUIBB CO.: COMPANY SNAPSHOT
  • TABLE 136.BRISTOL MYERS SQUIBB CO.: OPERATING SEGMENTS
  • TABLE 137.BRISTOL MYERS SQUIBB CO.: PRODUCT PORTFOLIO
  • TABLE 138.BRISTOL MYERS SQUIBB CO.: NET SALES,
  • TABLE 139.BRISTOL MYERS SQUIBB CO.: KEY STRATERGIES
  • TABLE 140.COGNOA INC: COMPANY SNAPSHOT
  • TABLE 141.COGNOA INC: OPERATING SEGMENTS
  • TABLE 142.COGNOA INC: PRODUCT PORTFOLIO
  • TABLE 143.COGNOA INC: NET SALES,
  • TABLE 144.COGNOA INC: KEY STRATERGIES
  • TABLE 145.CUREMARK LLC: COMPANY SNAPSHOT
  • TABLE 146.CUREMARK LLC: OPERATING SEGMENTS
  • TABLE 147.CUREMARK LLC: PRODUCT PORTFOLIO
  • TABLE 148.CUREMARK LLC: NET SALES,
  • TABLE 149.CUREMARK LLC: KEY STRATERGIES
  • TABLE 150.DFUSION INC.: COMPANY SNAPSHOT
  • TABLE 151.DFUSION INC.: OPERATING SEGMENTS
  • TABLE 152.DFUSION INC.: PRODUCT PORTFOLIO
  • TABLE 153.DFUSION INC.: NET SALES,
  • TABLE 154.DFUSION INC.: KEY STRATERGIES
  • TABLE 155.EARLITEC DIAGNOSTICS INC: COMPANY SNAPSHOT
  • TABLE 156.EARLITEC DIAGNOSTICS INC: OPERATING SEGMENTS
  • TABLE 157.EARLITEC DIAGNOSTICS INC: PRODUCT PORTFOLIO
  • TABLE 158.EARLITEC DIAGNOSTICS INC: NET SALES,
  • TABLE 159.EARLITEC DIAGNOSTICS INC: KEY STRATERGIES
  • TABLE 160.JAZZ PHARMACEUTICALS: COMPANY SNAPSHOT
  • TABLE 161.JAZZ PHARMACEUTICALS: OPERATING SEGMENTS
  • TABLE 162.JAZZ PHARMACEUTICALS: PRODUCT PORTFOLIO
  • TABLE 163.JAZZ PHARMACEUTICALS: NET SALES,
  • TABLE 164.JAZZ PHARMACEUTICALS: KEY STRATERGIES
  • TABLE 165.JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 166.JOHNSON & JOHNSON: OPERATING SEGMENTS
  • TABLE 167.JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 168.JOHNSON & JOHNSON: NET SALES,
  • TABLE 169.JOHNSON & JOHNSON: KEY STRATERGIES
  • TABLE 170.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 171.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 172.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 173.NOVARTIS AG: NET SALES,
  • TABLE 174.NOVARTIS AG: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.AUTISM SPECTRUM DISORDERS MARKET SEGMENTATION
  • FIGURE 2.AUTISM SPECTRUM DISORDERS MARKET,2021-2031
  • FIGURE 3.AUTISM SPECTRUM DISORDERS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.AUTISM SPECTRUM DISORDERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.AUTISM SPECTRUM DISORDERS MARKET,BY DISEASE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF AUTISTIC DISORDER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ASPERGER SYNDROME AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF PERVASIVE DEVELOPMENT DISORDER (PDD) AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 17.AUTISM SPECTRUM DISORDERS MARKET,BY SERVICE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF BEHAVIOURAL APPROACHES AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF EARLY INTERVENTION AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF MEDICATION AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHER SERVICES AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 22.AUTISM SPECTRUM DISORDERS MARKET,BY LOCATION,2021(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITALS AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF EDUCATION COUNSELLOR CENTER AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF OTHERS AUTISM SPECTRUM DISORDERS MARKET,2021-2031(%)
  • FIGURE 26.AUTISM SPECTRUM DISORDERS MARKET BY REGION,2021
  • FIGURE 27.U.S. AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 28.CANADA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 29.MEXICO AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 30.GERMANY AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 31.FRANCE AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 32.UK AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 33.ITALY AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 34.SPAIN AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 35.REST OF EUROPE AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 36.JAPAN AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 37.CHINA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 38.AUSTRALIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 39.INDIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 40.REST OF ASIA-PACIFIC AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 41.BRAZIL AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 42.SAUDI ARABIA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 43.SOUTH AFRICA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 44.REST OF LAMEA AUTISM SPECTRUM DISORDERS MARKET,2021-2031($MILLION)
  • FIGURE 45. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 46. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 47. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 48.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 49.COMPETITIVE DASHBOARD
  • FIGURE 50.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 51.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 52.AXIAL THERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 53.BRISTOL MYERS SQUIBB CO..: NET SALES ,($MILLION)
  • FIGURE 54.COGNOA INC.: NET SALES ,($MILLION)
  • FIGURE 55.CUREMARK LLC.: NET SALES ,($MILLION)
  • FIGURE 56.DFUSION INC..: NET SALES ,($MILLION)
  • FIGURE 57.EARLITEC DIAGNOSTICS INC.: NET SALES ,($MILLION)
  • FIGURE 58.JAZZ PHARMACEUTICALS.: NET SALES ,($MILLION)
  • FIGURE 59.JOHNSON & JOHNSON.: NET SALES ,($MILLION)
  • FIGURE 60.NOVARTIS AG.: NET SALES ,($MILLION)